Tryptophan 2,3-dioxygenase (TDO)-reactive T cells differ in their functional characteristics in health and cancer

OncoImmunology

Volumn 4, Issue 1, 2015, Pages 968480-

  Hjortsø, Mads Duus ^a   Larsen, Stine Kiaer ^a   Kongsted, Per ^a   Met, Özcan ^a   Frøsig, Thomas Mørch ^a   Andersen, Gitte Holmen ^a   Ahmad, Shamaila Munir ^a   Svane, Inge Marie ^a   Becker, Jürgen C ^b   Straten, Per thor ^a   Andersen, Mads Hald ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

immune regulation; T cells; TDO; Th17; Tregs

Indexed keywords

GAMMA INTERFERON; HLA A2 ANTIGEN; HLA ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 17; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TRYPTOPHAN 2,3 DIOXYGENASE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BREAST CANCER; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL FUNCTION; CELL ISOLATION; CELL STIMULATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOREACTIVITY; IMMUNOREGULATION; IN VITRO STUDY; MELANOMA; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PROTEIN EXPRESSION; RAPID EXPANSION PROTOCOL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TH1 CELL; TH17 CELL; TUMOR CELL LINE;

EID: 84938702166     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/21624011.2014.968480     Document Type: Article

References (36)

1. A.Muller, K.Heseler, S.K.Schmidt, K.Spekker, C.R.Mackenzie, W.Daubener. The missing link between indoleamine 2,3-dioxygenase mediated antibacterial and immunoregulatory effects. J Cell Mol Med 2009; 13:1125-35; PMID:19602041; dx.doi.org/10.1111/j.1582-4934.2008.00542.x
2. G.C.Prendergast, C.Smith, S.Thomas, L.Mandik-Nayak, L.Laury-Kleintop, R.Metz, A.J.Muller. Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. Cancer Immunol Immunother 2014; 63:721-35; PMID:24711084; dx.doi.org/10.1007/s00262-014-1549-4
3. Y.Zhang, S.A.Kang, T.Mukherjee, S.Bale, B.R.Crane, T.P.Begley, S.E.Ealick. Crystal structure and mechanism of tryptophan 2,3-dioxygenase, a heme enzyme involved in tryptophan catabolism and in quinolinate biosynthesis. Biochemistry 2007; 46:145-55; PMID:17198384; dx.doi.org/10.1021/bi0620095
4. D.Batabyal, S.R.Yeh. Human tryptophan dioxygenase: a comparison to indoleamine 2,3-dioxygenase. J Am Chem Soc 2007; 19:15690-701; PMID:18027945; dx.doi.org/10.1021/ja076186k
5. D.H.Munn, A.L.Mellor. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 2007; 117:1147-54; PMID:17476344; dx.doi.org/10.1172/JCI31178
6. D.H.Munn, M.D.Sharma, B.Baban, H.P.Harding, Y.Zhang, D.Ron, A.L.Mellor. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 2005; 22:633-42; PMID:15894280; dx.doi.org/10.1016/j.immuni.2005.03.013
7. C.A.Opitz, U.M.Litzenburger, F.Sahm, M.Ott, I.Tritschler, S.Trump, T.Schumacher, L.Jestaedt, D.Schrenk, M.Weller An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 2011; 478:197-203; PMID:21976023; dx.doi.org/10.1038/nature10491
8. G.C.Prendergast. Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene 2008; 27:3889-900; PMID:18317452; dx.doi.org/10.1038/onc.2008.35
9. G.C.Prendergast, R.Metz, A.J.Muller. IDO recruits Tregs in melanoma. Cell Cycle 2009; 8:1818-9; PMID:19471123; dx.doi.org/10.4161/cc.8.12.8887
10. C.Uyttenhove, L.Pilotte, I.Theate, V.Stroobant, D.Colau, N.Parmentier, T.Boon, B.J.Van den Eynde. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003; 9:1269-74; PMID:14502282; dx.doi.org/10.1038/nm934
11. R.Metz, J.B.DuHadaway, S.Rust, D.H.Munn, A.J.Muller, M.Mautino, G.C.Prendergast. Zinc protoporphyrin IX stimulates tumor immunity by disrupting the immunosuppressive enzyme indoleamine 2,3-dioxygenase. Mol Cancer Ther 2010; 9:1864-71; PMID:20530717; dx.doi.org/10.1158/1535-7163.MCT-10-0185
12. T.Z.Iversen, L.Engell-Noerregaard, E.Ellebaek, R.Andersen, S.K.Larsen, J.Bjoern, C.Zeyher, C.Gouttefangeas, B.M.Thomsen, B.Holm Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase. Clin Cancer Res 2014; 20:221-32; PMID:24218513; dx.doi.org/10.1158/1078-0432.CCR-13-1560
13. L.Pilotte, P.Larrieu, V.Stroobant, D.Colau, E.Dolusic, R.Frederick, E.De Plaen, C.Uyttenhove, J.Wouters, B.Masereel Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc Natl Acad Sci U S A 2012; 109:2497-502; PMID:22308364; dx.doi.org/10.1073/pnas.1113873109
14. R.B.Sorensen, L.Berge-Hansen, N.Junker, C.A.Hansen, S.R.Hadrup, T.N.Schumacher, E.De Plaen, C.Uyttenhove, J.Wouters, B.Masereel The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase. PLoS One 2009; 4:e6910; PMID:19738905; dx.doi.org/10.1371/journal.pone.0006910
15. R.B.Sorensen, S.R.Hadrup, I.M.Svane, M.C.Hjortso, P.thor Straten, M.H.Andersen. Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. Blood 2011; 117:2200-10; PMID:21079151; dx.doi.org/10.1182/blood-2010-06-288498
16. R.B.Sorensen, T.Kollgaard, R.S.Andersen, J.H.van den Berg, I.M.Svane, P.thor Straten, M.H.Andersen. Spontaneous cytotoxic T-Cell reactivity against indoleamine 2,3-dioxygenase-2. Cancer Res 2011; 71:2038-44; PMID:21406395; dx.doi.org/10.1158/0008-5472.CAN-10-3403
17. J.C.Becker, S.P.Thor, M.H.Andersen. Self-reactive T cells: suppressing the suppressors. Cancer Immunol Immunother 2014; 63:313-9; PMID:24368340; dx.doi.org/10.1007/s00262-013-1512-9
18. M.H.Andersen. The targeting of immunosuppressive mechanisms in hematological malignancies. Leukemia 2014; 28:1784-92; PMID:24691076; dx.doi.org/10.1038/leu.2014.108
19. J.D.Altman, P.A.Moss, P.J.R.Goulder, D.H.Barouch, M.G.McHeyzer Williams, J.I.Bell, A.J.McMichael, M.M.Davis. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996; 274:94-6; PMID:8810254; dx.doi.org/10.1126/science.274.5284.94
20. M.Toebes, M.Coccoris, A.Bins, B.Rodenko, R.Gomez, N.J.Nieuwkoop, W.van de Kasteele, G.F.Rimmelzwaan, J.B.Haanen, H.Ovaa Design and use of conditional MHC class I ligands. Nat Med 2006; 12:246-51; PMID:16462803; dx.doi.org/10.1038/nm1360
21. S.R.Bennett, F.R.Carbone, F.Karamalis, R.A.Flavell, J.F.Miller, W.R.Heath. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998; 393:478-80; PMID:9624004; dx.doi.org/10.1038/30996
22. C.A.Stewart, H.Metheny, N.Iida, L.Smith, M.Hanson, F.Steinhagen, R.M.Leighty, A.Roers, C.L.Karp, W.Müller, Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation. J Clin Invest 2013; 123:4859-74; PMID:24216477; dx.doi.org/10.1172/JCI65180
23. S.I.Grivennikov, K.Wang, D.Mucida, C.A.Stewart, B.Schnabl, D.Jauch, K.Taniguchi, G.Y.Yu, C.H.Osterreicher, K.E.Hung, Adenoma-linked barrier defects and microbial products drive IL-23IL-17-mediated tumour growth. Nature 2012; 491:254-8; PMID:23034650
24. W.W.Sung, Y.C.Wang, P.L.Lin, Y.W.Cheng, C.Y.Chen, T.C.Wu, H.Lee. IL-10 promotes tumor aggressiveness via upregulation of CIP2A transcription in lung adenocarcinoma. Clin Cancer Res 2013; 19:4092-103; PMID:23743567; dx.doi.org/10.1158/1078-0432.CCR-12-3439
25. Z.Chen, J.J.O’Shea. Th17 cells: a new fate for differentiating helper T cells. Immunol Res 2008; 41:87-102; PMID:18172584; dx.doi.org/10.1007/s12026-007-8014-9
26. W.Zou, N.P.Restifo. T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 2010; 10:248-56; PMID:20336152; dx.doi.org/10.1038/nri2742
27. S.Sakaguchi. Regulatory T cells. Springer Semin Immunopathol 2006; 28:1-2
28. M.S.Sundrud, C.Trivigno. Identity crisis of Th17 cells: many forms, many functions, many questions. Semin Immunol 2013; 25:263-72; PMID:24239567; dx.doi.org/10.1016/j.smim.2013.10.021
29. G.L.Stritesky, S.C.Jameson, K.A.Hogquist. Selection of self-reactive T cells in the thymus. Annu Rev Immunol 2012; 30:95-114; PMID:22149933; dx.doi.org/10.1146/annurev-immunol-020711-075035
30. S.Munir, S.K.Larsen, T.Z.Iversen, M.Donia, T.W.Klausen, I.M.Svane, P.T.Straten, M.H.Andersen. Natural CD4(+) T-cell responses against indoleamine 2,3-dioxygenase. PLoS One 2012; 7:e34568; PMID:22539948; dx.doi.org/10.1371/journal.pone.0034568
31. H.Quentmeier, R.A.MacLeod, M.Zaborski, H.G.Drexler. JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia 2006; 20:471-6; PMID:16408098; dx.doi.org/10.1038/sj.leu.2404081
32. H.G.Rammensee, K.Falk, O.Roetzschke. MHC molecules as peptide receptors. Curr Biol 1995; 5:35-44; PMID:7697344; dx.doi.org/10.1016/S0960-9822(95)00011-X
33. M.H.Andersen, L.O.Pedersen, J.C.Becker, thor P.Straten. Identification of a cytotoxic T lymphocyte response to the apoptose inhibitor protein surviving in cancer patients. Cancer Res 2001; 61:869-72; PMID:11221872
34. Z.Moodie, L.Price, S.Janetzki, C.M.Britten. Response determination criteria for ELISPOT: toward a standard that can be applied across laboratories. Methods Mol Biol 2012; 792:185-96; PMID:21956511; dx.doi.org/10.1007/978-1-61779-325-7_15
35. S.R.Hadrup, A.H.Bakker, C.J.Shu, R.S.Andersen, J.van Veluw, P.Hombrink, E.Castermans, P.Thor Straten, C.Blank, J.B.Haanen Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nat Methods 2009; 6:520-6; PMID:19543285; dx.doi.org/10.1038/nmeth.1345
36. M.H.Andersen, R.B.Sorensen, M.K.Brimnes, I.M.Svane, J.C.Becker, P.thor Straten. Identification of heme oxygenase-1-specific regulatory CD8+ T cells in cancer patients. J Clin Invest 2009; 119:2245-56; PMID:19662679; dx.doi.org/10.1172/JCI38739